group and 39% in the triple therapy group; 32% of the patients were taken off antihypertensive medications, 25% in the double therapy group and 39% in the triple therapy group. Then mean serum cholesterol level was 196 ::!:: 55 mg/dL, and was 200 ::!:: 62 mg/dL in the double therapy group, and 192 ::!:: 46 mg/dL in the triple therapy group.
Overall incidence of rejection was 36%; in the double therapy group, it was 44%, while in the triple therapy group.
it was 27% (P < .012). In the triple therapy patients who never came off MMF, the incidence of rejection was 16%, while in those discontinuing MMF, it was 49%. In addition, there was a trend toward more severe rejections in the double therapy group. The overall incidence of steroid-resistant rejection was 5.3%; in the double therapy group, it was 7.5%, whereas in the triple therapy group, it was 2.9%. The incidence of delayed graft function was 21 %, 21 % in the double therapy group, and 21 % in the triple therapy group. Incidence of cytomegalovirus was 12.5%, 8.5% in the double therapy group and 16.7% in the triple therapy group (P = NS). The initial and final incidences of posttransplant diabetes mellitus were, respectively, 7.0% and 2.9%, 9.3% and 4.7% in the double therapy group, and 4.7% and 1.2% in the triple therapy group. The overall incidence of crossover was 31%,28% from double to triple therapy, and 34% from triple therapy to double therapy; in the second year of the trial, the incidence of crossover from triple to double therapy decreased to 12%.
These data suggest that the combination of tacrolimus, mycophenolate, and prednisone is associated with a lower incidence of rejection than the combination of tacrolimus and steroids, although there is no difference in patient or graft survival at 1 year. There are side effects associated with triple therapy, but they have been generally manageable with dosage reduction. Finally, this trial suggests that the combination of tacrolimus and MMF is associated with excellent patient and graft survival, and a low incidence of rejection.
